相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response
Toni T. Seppala et al.
CLINICAL CANCER RESEARCH (2022)
Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections
Ram K. Modukuri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
BET Proteins as Attractive Targets for Cancer Therapeutics
Joanna Sarnik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Achieving clinical success with BET inhibitors as anti-cancer agents
Tatiana Shorstova et al.
BRITISH JOURNAL OF CANCER (2021)
A Potent, Selective CBX2 Chromodomain Ligand and Its Cellular Activity During Prostate Cancer Neuroendocrine Differentiation
Sijie Wang et al.
CHEMBIOCHEM (2021)
Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library
Yu Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Discovery of a Highly Selective BET BD2 Inhibitor from a DNA-Encoded Library Technology Screening Hit
Francesco Rianjongdee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Kunal Nepali et al.
JOURNAL OF BIOMEDICAL SCIENCE (2021)
EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer
Hwa-Ryeon Kim et al.
NAR CANCER (2021)
Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins
Justin M. Rectenwald et al.
MOLECULES (2020)
Epigenetic Therapy for Epithelioid Sarcoma
Scott B. Rothbart et al.
CELL (2020)
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer
P. Jake Slavish et al.
CANCER RESEARCH (2020)
Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Mariano Ponz-Sarvise et al.
CLINICAL CANCER RESEARCH (2019)
The timeline of epigenetic drug discovery: from reality to dreams
A. Ganesan et al.
CLINICAL EPIGENETICS (2019)
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Yuan Cheng et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
DNA-encoded libraries - an efficient small molecule discovery technology for the biomedical sciences
Verena Kunig et al.
BIOLOGICAL CHEMISTRY (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Hatice Gulcin Ozer et al.
CANCER DISCOVERY (2018)
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
Garrett W. Rhyasen et al.
PLOS ONE (2018)
BRD4 and Cancer: going beyond transcriptional regulation
Benedetta Donati et al.
MOLECULAR CANCER (2018)
HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues
Xiaoyu Lin et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Epigenetic plasticity and the hallmarks of cancer
William A. Flavahan et al.
SCIENCE (2017)
Targeting Cancer Cells with BET Bromodomain Inhibitors
Yali Xu et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action
Amaury E. Fernandez-Montalvan et al.
ACS CHEMICAL BIOLOGY (2017)
Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4
Michael D. Olp et al.
BIOCHEMISTRY (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Ana S. Leal et al.
CANCER LETTERS (2017)
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Maria E. Riveiro et al.
ONCOTARGET (2016)
Targeting bet bromodomain proteins in solid tumors
Vaibhav Sahai et al.
ONCOTARGET (2016)
High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML
Yue Zhao et al.
CELL REPORTS (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
Xu Ran et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
Jae-Seok Roe et al.
MOLECULAR CELL (2015)
Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors
Steven G. Smith et al.
CHEMISTRY & BIOLOGY (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
Kevin G. McLure et al.
PLOS ONE (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Sarah Picaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution
Friederike Vollmuth et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Histone deacetylase inhibitors: discovery and development as anticancer agents
PA Marks et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
分享论文
